Thyroid dysfunction in patients with metastatic carcinoma treated with Sunitinib: is thyroid autoimmunity involved?

Sunitinib is a tyrosine kinase inhibitor (TKI) inducing thyroid dysfunction, but the precise mechanism(s) involved remains to be explained, including a role of thyroid autoimmunity. The objective was to evaluate thyroid function, parameters of autoimmunity, and thyroid ultrasound findings in patients with metastatic cancer and normal thyroid function/autoimmunity before the initiation of Sunitinib therapy. This is a prospective, observational cohort study